<DOC>
	<DOCNO>NCT01335971</DOCNO>
	<brief_summary>Evidence investigator ' group show chronic obstructive pulmonary disease ( COPD ) patient impairment antioxidant defense cause defect activity Nrf2 . This trial focus sulforaphane , derivative cruciferous vegetable , potent stimulator Nrf2 activity . The investigator want investigate whether ingestion sulforaphane COPD patient increase Nrf2 activity expression downstream antioxidant . Accordingly , investigator conduct placebo-controlled randomized proof principle trial two oral dos sulforaphane , 25 150 micromoles , 4 week 90 COPD patient . The investigator ' goal establish safe tolerable dose sulforaphane effect vivo antioxidant via Nrf2 , investigator novel candidate treatment longer-term efficacy trial .</brief_summary>
	<brief_title>Broccoli Sprout Extracts Trial</brief_title>
	<detailed_description>Chronic Obstructive Pulmonary Disease ( COPD ) major cause morbidity mortality United States grow cause chronic disease internationally . Presently , limited treatment option disease modify progression airflow obstruction decrease periodic exacerbation . Recent evidence emphasize central role oxidative stress mechanism COPD pathobiology . Evidence investigator ' group show COPD patient animal expose cigarette smoke impairment antioxidant defense cause defect activity Nrf2 , prolific regulator anti-oxidant enzyme , glutathione homeostasis , cytoprotective protein . Activation Nrf2 protect mice chronic smoke exposure develop emphysema , decrease oxidative stress , increase proteasomal anti-apoptotic cytoprotective response , improve bacterial phagocytosis killing , reverse tobacco-smoke induced corticosteroid resistance . Similarly , vitro Nrf2 activation human COPD lung cell show improved cytoprotection , improve bacterial clearance , restoration steroid sensitivity . This trial focus sulforaphane , derivative cruciferous vegetable , potent vitro vivo stimulator Nrf2 activity . The investigator want investigate whether ingestion sulforaphane chronic obstructive pulmonary disease ( COPD ) patient increase Nrf2 activity expression downstream antioxidant alveolar macrophage bronchial epithelial cell . Accordingly , investigator conduct placebo-controlled randomized proof principle trial two oral dos sulforaphane , 25 150 micromoles , 4 week 90 COPD patient . Collections alveolar macrophage Bronchoalveolar lavage ( BAL ) , bronchial epithelial cell endobronchial brushing perform baseline 4 week . Other bio-specimens include nasal epithelial cell , Peripheral Blood Monocyte Collection ( PBMCs ) , expire breath condensate ( EBC ) . The investigator ' goal establish safe tolerable dose sulforaphane effect vivo antioxidant via Nrf2 , investigator novel candidate treatment longer-term efficacy trial . Ancillary study propose explore efficacy mechanism sulforaphane increase bacterial clearance restore steroid sensitivity COPD lung cell .</detailed_description>
	<mesh_term>Sulforafan</mesh_term>
	<criteria>1 . Age 40 year great , either sex 2 . 10 packyears smoke history 3 . Physician diagnose COPD 4 . Post bronchodilator Forced expiratory volume 1 second ( FEV1 ) / force expiratory vital capacity ( FVC ) ratio &lt; 0.70 5 . FEV1 4080 % predict 6 . Willingness ingest 1 serve cruciferous vegetable per week runin treatment period 7 . Ability willingness provide inform consent 1 . COPD exacerbation within precede 6 week require treatment 2 . Significant respiratory ( COPD ) , cardiovascular , neuropsychiatric , renal , gastrointestinal , genitourinary disease would interfere participation study interpretation result . 3 . Acute Myocardial infarction ( MI ) Acute Coronary syndrome within 6 prior month 4 . Cancer ( skin localize prostate ) within precede 5 year 5 . Childbearing potential lack adequate contraception , Pregnancy lactation . Acceptable form birth control include abstinence , hysterectomy , tubal ligation , two following : vasectomy , condom , diaphragm , intrauterine device , oral implanted contraceptive , spermicide . 6 . Allergy local anesthesia 7 . Resting hypoxemia ( O2 saturation &lt; 90 % ) 8 . Glomerular Filtration Rate ( GFR ) &lt; 30 9 . Liver enzymes four time upper normal 10 . Current use warfarin indication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>COPD</keyword>
	<keyword>Nrf2</keyword>
	<keyword>Sulforaphane</keyword>
</DOC>